| Name | Acetazolamide sodium |
| Description | Acetazolamide sodium (OT-302 sodium) is a potent carbonic anhydrase (CA)IX inhibitor with diuretic, antigonococcal, and antihypertensive activity and may be used for indications such as epilepsy, glaucoma, edema, and altitude sickness. |
| In vitro | The combination of Acetazolamide sodium (0-160 μM) with MS-275 (0.75 μM) exhibited dose-dependent inhibition of growth, induced cell cycle arrest and apoptosis, and reduced migration ability in NB cell line SH-SY5Y[1]. |
| In vivo | In preclinical xenograft models, treatment with AZ (40 mg/kg), MS-275 (20 mg/kg), and AZ + MS-275 (40 + 20 mg/kg) for 14 days significantly inhibited tumor growth in vivo. The expression of HIF-1α and CAIX markedly decreased, while apoptosis in NB xenograft cells of SH-SY5Y significantly increased[1]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 80 mg/mL (4.08 mM), Sonication is recommended.
DMSO : 80 mg/mL (4.08 mM), Sonication is recommended.
|
| Inhibitors Related | Benzenesulfonamide | Urea | Cyclamic acid sodium | Orthanilamide | Tioxolone | Zonisamide | Histone acetyltransferase p300 Inhibitor 4c | EMAC10101d | pNNP | Trichlormethiazide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Bioactive Compounds Library Max |
United States
